drugset / Trial / NCT01511783
Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-07
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elenbecestat | Small molecule | 25 mg | Oral |
| Subject | Elenbecestat | Small molecule | 50 mg | Oral |
| Subject | Elenbecestat | Small molecule | 200 mg | Oral |
Indications
No indication recorded.